What Is Psoriasis? A Complete Guide to Causes, Symptoms, and Treatment

Psoriasis is not just a skin condition. It is a chronic, immune-driven disease that can affect the joints, the heart, the mind, and the metabolism, alongside the skin.

This guide brings together current research, clinical guidelines, and epidemiological data to explain psoriasis in depth. It is written for patients who want clarity and for readers, including caregivers, students, and healthcare professionals, who want a medically accurate, well-referenced resource they can return to.

We cover everything from the biology behind psoriasis to its treatment, complications, and the reasons ongoing medical supervision matters so much. Wherever helpful, we point to related topics — such as psoriatic arthritis or biologic therapy — that deserve their own deeper reading.

What Is Psoriasis?

Psoriasis has been recognized as a distinct condition since antiquity, though it was frequently confused with leprosy and other skin diseases for centuries. It was not clearly separated from other scaly skin conditions until the nineteenth century, and its immune basis was only firmly established in recent decades.

Today, psoriasis sits within a broader family of conditions dermatologists call immune-mediated inflammatory diseases, alongside rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis. This classification matters because it explains why so many treatments for psoriasis were originally developed for, or later found effective in, these related conditions.

Psoriasis is a chronic, relapsing, immune-mediated inflammatory skin disease. It causes skin cells to grow far faster than normal, piling up into thick, scaly, red or discolored patches called plaques.

Unlike a simple rash, psoriasis is a systemic disease. The same inflammatory pathways that cause skin plaques can also affect joints, blood vessels, and metabolic health.

There is currently no cure for psoriasis. However, with modern treatment, most people can achieve clear or nearly clear skin and live full, active lives.

A Quick Pathophysiology Snapshot

At its core, psoriasis reflects a miscommunication between the immune system and the skin. Immune cells send inflammatory signals that tell skin cells to multiply far faster than they should, and the skin cannot shed this extra tissue quickly enough.

The result is the buildup of thick, scaly plaques on the surface. We explain this process in full detail in the etiopathogenesis section below, since understanding it is key to understanding why modern treatments work the way they do.

Who Gets Psoriasis?

Psoriasis can begin at any age, from infancy to late adulthood, though two peaks are commonly described. Most patients are diagnosed either in their late teens to thirties, or later, in their fifties to sixties, with somewhat different disease patterns in each group.

Men and women are affected in roughly equal numbers overall. However, as covered in the epidemiology section, the timing and pace of onset can differ somewhat between sexes and across the lifespan.

Psoriasis can affect people of every skin tone and ethnic background. That said, presentation can look different depending on skin tone, and it is sometimes under diagnosed or diagnosed later in people with darker skin, a point we return to in the clinical aspects section.

Epidemiology: How Common Is Psoriasis?

Psoriasis affects people across every continent, though rates vary widely by region and ethnicity. Understanding these patterns helps explain why psoriasis is treated as a major global health issue, not a cosmetic concern.

Global Prevalence

Worldwide, roughly 2 to 3% of the population, or an estimated 125 million people, live with psoriasis, according to the World Psoriasis Day consortium. Plaque psoriasis, the most recognizable form, accounts for 80 to 90% of all psoriasis cases.

Global Burden of Disease data tells a similar story from a different angle. Between 1990 and 2021, global psoriasis prevalence rose from about 23.06 million to 42.98 million cases, an 86% increase, while new cases climbed by 80%.

Disability linked to psoriasis has grown too. Over the same period, psoriasis-related disability-adjusted life years rose from 2.00 million to 3.69 million, an 85% increase, even as treatment options expanded.

Regional and Demographic Patterns

Psoriasis is not distributed evenly across the globe. The highest disease burden in 2021 was concentrated in high-income regions such as Western Europe and North America, where age-standardized prevalence rates exceeded 850 per 100,000 people.

By contrast, East Asia and sub-Saharan Africa showed substantially lower disease estimates, though researchers note this may partly reflect limited data collection rather than true lower rates. Newer modeling also shows disease onset patterns differ by sex.

Incidence rates among boys and girls are similar during childhood and adolescence, but incidence rises sharply with age among men later in life. Age-standardized incidence has been trending upward for decades, and this trend is expected to continue.

Age-standardized incidence rates increased from 1990 to 2021 by 10.3% in men and 7.3% in women, and are projected to keep rising through 2050, according to Global Burden of Disease projections. This means psoriasis is, unfortunately, becoming more common rather than less.

The Economic Burden

Psoriasis carries a heavy financial cost, both to patients and to health systems. In the United States alone, researchers estimate the direct costs of psoriasis range from $51.7 billion to $63.2 billion annually, with indirect costs of $23.9 billion to $35.4 billion and comorbidity-related costs of about $36.4 billion, adding up to a total burden between $112 billion and $135 billion.

Globally, the picture is just as striking. One 2021 analysis placed the worldwide economic burden of psoriasis at $148.85 billion, split between $95.15 billion in healthcare costs and $53.70 billion in lost productivity.

These figures underline a point dermatologists have made for years: psoriasis is a public health issue, not a minor skin complaint.

Etiopathogenesis: What Causes Psoriasis?

Psoriasis develops from a complex interaction between genes, the immune system, and environmental triggers. No single cause explains every case, which is part of why treatment must often be personalized.

Genetic Susceptibility

Family history is one of the strongest risk factors for psoriasis. Genome-wide association studies have identified dozens of genetic regions linked to disease risk.

The most significant of these is a region on chromosome 6. Researchers estimate that roughly one-third of the genetic risk for psoriasis is linked to the major histocompatibility complex region, with the strongest single locus, PSORS1, located within this site.

Having these genes does not guarantee disease. Most experts believe an environmental trigger is usually needed to “switch on” psoriasis in a genetically susceptible person.

The Immune Pathway: IL-23 and Th17 Cells

The modern understanding of psoriasis centers on a specific immune signaling loop. This is often called the IL-23/Th17 axis, and it has reshaped how psoriasis is treated over the last fifteen years.

In this pathway, dendritic cells and macrophages in the skin release a cytokine called IL-23, which is secreted by dendritic cells and macrophages and stimulates the differentiation and proliferation of Th17 cells, acting as an upstream regulatory cytokine in psoriasis. Activated Th17 cells then release their own inflammatory messengers.

Chief among these is IL-17. IL-17A overproduction triggers a self-perpetuating cycle of inflammation, involving cytokines, chemokines, and antimicrobial peptides that drive epidermal hyperplasia and innate immune activation.

Other cytokines amplify this loop further. IL-23 also activates Th17 cells to release IL-17, IL-22, and TNF-alpha, each of which contributes to further inflammatory responses in the skin.

This inflammatory loop directly explains why skin cells in psoriasis multiply so rapidly. Normal skin cells take roughly a month to mature and shed; in psoriatic plaques, this process can compress into just a few days, causing the buildup of scale.

Keratinocytes Are Not Passive Bystanders

For years, psoriasis was viewed mainly as a T-cell disease acting on passive skin cells. Newer research shows the skin cells themselves, called keratinocytes, actively amplify the inflammatory signal rather than simply reacting to it.

A key pathogenic loop in psoriasis involves a triad of IL-23-producing dendritic cells, IL-17-producing Th17 cells, and activated keratinocytes, working together in a feedback circuit. Genetic mutations affecting keratinocyte signaling, including in the IL-36 and CARD14 genes, have been linked to familial and pustular forms of psoriasis, reinforcing this concept.

HLA-Cw6 and Early-Onset Disease

One specific genetic marker deserves special mention because of how strongly it shapes disease patterns. The HLA-Cw6 variant, part of the same MHC region discussed above, is strongly associated with earlier disease onset and a stronger link to guttate flares following strep throat infection.

People carrying this marker are more likely to develop psoriasis before age 40. This genetic distinction is part of why some researchers now describe “type 1” (early-onset, HLA-Cw6-linked) and “type 2” (later-onset) psoriasis as somewhat distinct clinical patterns.

The Koebner Phenomenon

Skin trauma is one of the most reliable and well-documented psoriasis triggers. The Koebner phenomenon describes new psoriasis plaques forming at sites of skin injury, including cuts, sunburn, tattoos, insect bites, and even repeated friction from tight clothing.

This reaction typically appears seven to fourteen days after the injury, though timing varies. Recognizing this pattern helps patients understand why protecting the skin from unnecessary trauma is a genuinely useful, evidence-based piece of everyday advice.

Infections as Triggers

Beyond streptococcal throat infections linked to guttate psoriasis, other infections can also destabilize disease control. Viral illnesses, skin infections, and even some vaccinations have been reported, less commonly, to precede flares in susceptible individuals.

This does not mean vaccination should be avoided; the benefits of standard immunizations far outweigh this small theoretical risk for almost all patients. It does mean flares around the time of an infection are worth mentioning to a treating physician, since it can help clarify a patient’s personal trigger pattern.

Medications That Can Trigger or Worsen Psoriasis

Certain drug classes are well documented to induce new psoriasis or worsen existing disease. These include lithium, certain beta-blockers, antimalarial drugs, and, notably, the abrupt withdrawal of systemic corticosteroids, which can trigger a severe rebound flare.

Anyone starting a new long-term medication for an unrelated condition should mention their psoriasis history to the prescribing physician. This simple step allows a more informed choice between therapeutic alternatives when one exists.

Hormonal and Stress-Related Triggers

Hormonal shifts, including puberty, menopause, and pregnancy, can all influence disease activity, sometimes in unpredictable directions, as discussed further in the pregnancy section below. Psychological stress is one of the most commonly self-reported triggers among patients, and it appears to act through measurable effects on immune signaling rather than being a purely subjective association.

Environmental and Lifestyle Triggers

Genetics load the gun, but environmental factors often pull the trigger. Common triggers include skin injury (the Koebner phenomenon), streptococcal throat infections, certain medications, stress, smoking, and alcohol use.

Metabolic and lifestyle factors also play a documented role. Large-scale modeling has linked psoriasis risk and severity to obesity, physical inactivity, air pollution, and ultraviolet radiation exposure, among other factors.

Cold, dry climates are frequently reported to worsen symptoms, while sunlight in moderation often helps, which is part of the biological rationale behind phototherapy discussed later. Excessive sun exposure and sunburn, however, can themselves trigger Koebnerization and should be avoided.

The Microbiome Connection

Emerging research points to another contributor: the balance of microorganisms living on the skin and in the gut. Dysbiosis, triggered by genetic or external factors, can drive a burst of pro-inflammatory effects, with both the skin and gut microbiome implicated in the disease process.

This is an active area of research, and it may eventually open new treatment avenues. For now, it reinforces that psoriasis genuinely is a whole-body condition, not simply a skin-deep one.

Clinical Aspects: Types, Symptoms, and Presentation

Psoriasis can look different depending on which subtype a person has, where it appears on the body, and their skin tone. Recognizing these patterns is central to accurate diagnosis.

Plaque Psoriasis

Plaque psoriasis, also called psoriasis vulgaris, is by far the most common form. It presents as well-demarcated, raised, scaly plaques, often on the scalp, elbows, knees, and lower back.

On lighter skin, plaques often appear red or pink with silvery-white scale. On medium to darker skin tones, plaques may appear violet, brown, or grey, and the surrounding scale can be less obviously silver, which sometimes delays diagnosis.

Guttate Psoriasis

Guttate psoriasis appears as small, drop-shaped spots scattered across the trunk and limbs. It is most common in children and young adults and is frequently triggered by a streptococcal throat infection a week or two before the outbreak.

Many guttate flares resolve on their own within weeks to months. In some patients, however, guttate psoriasis evolves into chronic plaque psoriasis over time.

Inverse (Flexural) Psoriasis

Inverse psoriasis develops in skin folds — under the breasts, in the armpits, groin, and around the genitals. Because these areas are moist and friction-prone, plaques here tend to be smooth and shiny rather than thickly scaled.

This form is often misdiagnosed as a fungal or yeast infection. Careful clinical examination, and sometimes biopsy, helps distinguish it from true infections.

Pustular Psoriasis

Pustular psoriasis is a less common but more severe variant. It features white pustules of noninfectious pus surrounded by red skin, and it can be localized to the palms and soles or generalized across the body.

Generalized pustular psoriasis is considered a medical emergency. It can trigger fever, chills, severe illness, and electrolyte imbalances, and it requires urgent hospital-based care.

Erythrodermic Psoriasis

Erythrodermic psoriasis is the rarest and most dangerous subtype. It causes widespread redness and scaling covering nearly the entire body surface, disrupting the skin’s ability to regulate temperature and retain fluid.

This form can be life-threatening due to risks of infection, dehydration, and heart strain. Any suspected erythrodermic flare needs immediate medical attention.

Nail Psoriasis

Up to half of people with psoriasis develop nail changes at some point known as nail psoriasis. These include pitting, discoloration, thickening, and separation of the nail from the nail bed, a finding called onycholysis.

Nail involvement is more than cosmetic. It is strongly associated with psoriatic arthritis, so nail changes should prompt a joint assessment.

Scalp Psoriasis

Scalp psoriasis can range from mild flaking that resembles severe dandruff to thick, crusted plaques covering the entire scalp. It sometimes extends slightly past the hairline onto the forehead, ears, or neck.

Temporary hair thinning can occur in severely affected areas, usually due to scratching or plaque thickness rather than the disease itself. Hair typically regrows once inflammation is controlled.

Itch, Pain, and Physical Discomfort

Psoriasis is often assumed to be a purely cosmetic issue, but physical discomfort is common and sometimes severe. Itching affects the majority of patients and can be intense enough to disrupt sleep and concentration.

Painful cracking and bleeding, especially over joints, on the palms, soles, or in skin folds, is another frequent complaint. This physical burden is part of why quality-of-life scoring, discussed under investigations, captures more than skin appearance alone.

Psoriasis in Skin of Color

Recognizing psoriasis in patients with medium to dark skin tones requires particular attention, since classic descriptions of “red plaques with silvery scale” were historically written with lighter skin in mind. Plaques may appear violet, dark brown, or grey-black, and post-inflammatory pigment changes — either darkening or lightening of skin after a plaque resolves — are more prominent and can persist for months.

Clinical trial data and epidemiological studies have also historically underrepresented patients with skin of color, which has contributed to delayed diagnosis and undertreatment in some populations. Patients and clinicians alike benefit from being aware of this gap, and from seeking dermatologists experienced in recognizing disease presentation across all skin tones.

Differential Diagnosis

Several skin conditions can resemble psoriasis, which is why an experienced clinical eye — and, at times, a biopsy — matters. Seborrheic dermatitis, eczema, tinea (fungal infection), lichen planus, and cutaneous T-cell lymphoma are among the most common look-alikes.

Distinguishing between these matters because treatment approaches differ substantially. Topical steroids that help psoriasis, for instance, can worsen an unrecognized fungal infection, which is one more reason self-diagnosis from photos online is risky.

Measuring Severity

Dermatologists commonly grade psoriasis severity using two related tools. The Psoriasis Area and Severity Index, or PASI, and Body Surface Area, or BSA, both help quantify how much skin is affected and how inflamed it looks.

As a general rule, disease affecting less than 3% to 5% of body surface area is classified as mild, while more than 5% is considered moderate to severe. This classification guides treatment decisions, discussed later in this guide.

Pediatric Psoriasis

Psoriasis is often thought of as an adult disease, but it frequently begins in childhood. Roughly a third of all cases start before age 20, making pediatric psoriasis an important and sometimes overlooked category.

How It Differs From Adult Psoriasis

Children more often present with guttate psoriasis, frequently following a strep throat infection. Facial and scalp involvement is also more common in children than in adults, and plaques may be thinner and less scaly.

Diaper area involvement is a distinctive pattern seen in infants. This can be mistaken for simple diaper rash, delaying correct diagnosis.

Screening for Comorbidities Early

Children with psoriasis are not exempt from the systemic risks associated with the disease. Pediatric dermatology guidelines now recommend comorbidity screening from the time of diagnosis, covering weight, blood pressure, and mental health.

Early, proactive screening matters because metabolic and psychological patterns established in childhood often persist into adulthood. Catching problems early gives families a chance to intervene before complications become entrenched.

Treating Psoriasis in Children

Mild pediatric psoriasis is usually managed with gentle topical treatments and moisturizers, alongside trigger avoidance. For moderate to severe disease, phototherapy and, when appropriate, systemic or biologic treatment may be used under specialist supervision.

Several biologic medications now carry pediatric approval for moderate to severe plaque psoriasis. Even so, treatment in children always requires closer monitoring than in adults, given growing bodies and long treatment horizons ahead.

The Emotional Dimension in Young Patients

Children and teenagers with visible psoriasis face unique social pressures at school and among peers. Bullying, teasing, and self-consciousness about appearance are commonly reported, and can affect academic performance and social development if unaddressed.

Parents and pediatricians play a critical role in watching for these signs, since children may not volunteer them directly. Involving a psychologist or counselor alongside dermatologic care is increasingly recognized as good practice for young patients with more than mild disease.

Family Planning for Growing Bodies

Because pediatric patients are still growing, treatment decisions must weigh long-term safety more heavily than they might in an adult starting the same therapy later in life. This is one reason phototherapy and topical treatment are favored first for milder cases, reserving systemic options for children whose disease significantly affects daily function.

Growth, weight, and pubertal development are typically tracked alongside skin response during systemic treatment. Regular pediatric dermatology follow-up allows these factors to be monitored together, rather than in isolation. (Internal link opportunity: “A Parent’s Guide to Managing Childhood Psoriasis”)

Psoriasis and Pregnancy

Psoriasis commonly affects women during their reproductive years, which makes pregnancy planning an essential conversation between patients and their dermatologists. Three-quarters of patients develop psoriasis before their fourth decade of life, meaning many women will need to manage the disease through pregnancy and breastfeeding.

How Pregnancy Affects Psoriasis

Pregnancy has an unpredictable effect on disease activity. For many pregnant women, psoriasis improves during pregnancy, but for a minority, flares occur instead, often related to shifting hormone levels.

Impetigo Herpetiformis: A Pregnancy-Specific Emergency

A rare but serious variant, impetigo herpetiformis, can develop during pregnancy, typically in the third trimester. It is now understood as a form of generalized pustular psoriasis that develops during, or is triggered by, pregnancy, and it demands urgent specialist care.

The condition can be dangerous for both mother and baby. It is distinguished by a potentially deadly prognosis for both the mother and the baby if left untreated, and cases have been linked to placental insufficiency and stillbirth risk.

Symptoms extend beyond the skin. Constitutional signs can include malaise, fever, delirium, diarrhea, and vomiting, along with laboratory abnormalities such as elevated white cell counts and low calcium levels that can cause tetany.

Choosing Safe Treatments

Not every psoriasis medication is safe during pregnancy, so treatment plans need careful adjustment. Topical retinoids and dithranol should be avoided, while simple emollients and appropriately potent topical steroids can generally be used.

Phototherapy is often considered a reasonable option during pregnancy. Oral PUVA photochemotherapy carries a theoretical mutagenic risk that has not been substantiated by detailed studies, but it is still best avoided in pregnancy as a precaution.

Biologic therapy decisions require close specialist input. A conservative approach many clinicians use is to stop biologic and small-molecule medications at least five half-lives before conception, weighing this against the risks of uncontrolled inflammation.

That trade-off is real and important. Active psoriasis involves body-wide inflammation, and the risk to the unborn baby from uncontrolled inflammation must be weighed against the risk from medication — a decision that should never be made without a dermatologist’s guidance.

Methotrexate and oral retinoids are strictly off-limits. Both are classified as contraindicated in pregnancy due to well-documented risks of birth defects, and effective contraception is essential while taking them and for a defined period afterward.

This is precisely why pregnancy planning conversations should start early. Anyone with psoriasis who is considering pregnancy should discuss their current medications with their dermatologist well before conception.

Breastfeeding Considerations

Treatment decisions do not end at delivery, since many patients also need guidance about breastfeeding. Topical treatments used on areas away from the breast are generally considered compatible with breastfeeding, though care is taken to avoid application near the nipple area.

Certain biologics are increasingly considered compatible with breastfeeding, based on data showing minimal transfer into breast milk, but this varies by specific drug and should always be confirmed with a treating physician. Methotrexate and oral retinoids remain contraindicated during breastfeeding, just as in pregnancy.

Postpartum Flare Risk

Many patients experience a flare in the weeks after delivery, even if their disease improved during pregnancy itself. This is thought to relate to the rapid hormonal shifts that follow childbirth, and anticipating it can help patients and physicians plan a treatment transition in advance rather than reactively.

Unique and Lesser-Known Aspects of Psoriasis

Beyond the well-known plaques and triggers, psoriasis has several distinctive features that set it apart from other chronic skin conditions. These lesser-known aspects reveal just how unusual — and scientifically interesting — this disease really is.

What Twin Studies Reveal

Identical twin studies offer some of the strongest evidence for how heavily genetics shapes psoriasis risk. When one identical twin has psoriasis, the other develops it in a large majority of cases, a concordance rate far higher than seen in fraternal twins raised in the same environment.

This gap between identical and fraternal twin outcomes is one of the clearest signals in all of dermatology that a disease has a powerful inherited component. Yet because concordance is high rather than universal, it also confirms that genetics alone does not fully determine outcome — environment and trigger exposure still matter.

Paradoxical Psoriasis

One of the strangest features of psoriasis is that the very drugs used to treat it can, in different patients, sometimes trigger it. TNF-alpha inhibitors, prescribed for conditions like rheumatoid arthritis or inflammatory bowel disease, occasionally cause a new psoriasis-like rash in patients who never had psoriasis before, a phenomenon known as paradoxical psoriasis.

This counterintuitive reaction is thought to relate to an imbalance created when TNF is blocked, allowing other inflammatory pathways, including interferon signaling, to become more active in the skin. It is a striking reminder that the immune system’s balance is delicate, and that blocking one pathway can sometimes unmask another.

A Disease With a Geographic Gradient

Psoriasis prevalence is not random across the globe; it tends to rise the further a population lives from the equator. This pattern lines up with lower average ultraviolet light exposure at higher latitudes, reinforcing the biological link between sunlight, immune regulation, and disease activity discussed under phototherapy.

Seasonal fluctuation follows the same logic on an individual level. Many patients notice their skin improves in summer and worsens in winter, tracking natural changes in sun exposure and humidity throughout the year.

The Rebound Phenomenon

Psoriasis has a distinctive and clinically important behavior when certain treatments are stopped abruptly: it can flare back more severely than before treatment began. This rebound effect is best documented with systemic corticosteroids and, in some cases, after discontinuing certain systemic therapies without a proper taper or transition plan.

This is precisely why psoriasis medications, particularly systemic ones, should never be stopped abruptly without medical guidance. A physician-supervised transition plan helps avoid this uniquely psoriasis-specific risk.

An Unusual Bone and Joint Connection: SAPHO Syndrome

A rare but fascinating association exists between certain pustular forms of psoriasis and a cluster of bone and joint symptoms known as SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis). This connection illustrates, in an especially vivid way, just how far beyond the skin psoriatic inflammation can reach.

While rare, SAPHO syndrome is a useful teaching example for why unexplained bone pain in a patient with pustular psoriasis should never be dismissed as unrelated. It reflects the same systemic inflammatory biology discussed throughout this guide, simply expressed in an uncommon location.

Psoriasis That Starts in the Nails Alone

In a small subset of patients, nail changes can appear years before any visible skin plaque develops. This unusual presentation can lead to long diagnostic delays, since isolated nail changes are far more often assumed to be a fungal infection than an early sign of psoriasis.

Recognizing this pattern matters clinically, since these patients often go on to develop more classic skin or joint disease later. It is one more example of why a dermatologist’s trained eye, rather than assumption, is valuable even for seemingly minor or isolated symptoms.

Psoriasis as a Systemic Disease

Perhaps the single most important shift in psoriasis understanding over the past two decades is this: psoriasis is not confined to the skin. It behaves like a systemic inflammatory disease, similar in some ways to rheumatoid arthritis or inflammatory bowel disease.

Psoriatic Arthritis

Up to 30% of people with psoriasis eventually develop psoriatic arthritis, a form of inflammatory joint disease. It can cause joint pain, stiffness, swelling, and, if untreated, irreversible joint damage.

Nail changes, as mentioned earlier, are a red flag for joint involvement. Anyone with psoriasis who develops new joint pain or stiffness should be evaluated promptly, since early treatment protects long-term joint function.

Metabolic and Cardiovascular Links

Psoriasis is consistently associated with higher rates of obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol levels. These are not simply coincidental; they share inflammatory biology with psoriasis itself.

Cardiovascular disease is the most serious of these associations. The inflammatory cutaneous-to-systemic expansion seen in psoriasis patients may cause systemic immune-mediated alterations that lead to important comorbidities, including diabetes, obesity, hypertension, dyslipidemia, and cardiovascular disease.

Metabolic Syndrome

Metabolic syndrome — the cluster of abdominal obesity, high blood pressure, high blood sugar, and abnormal cholesterol — occurs more frequently in people with psoriasis than in the general population, and the association strengthens with disease severity. Shared inflammatory pathways, rather than coincidence, are thought to explain much of this overlap.

This is one more reason severity assessment matters beyond the skin. A patient with extensive plaques is statistically more likely to be carrying unrecognized metabolic risk that deserves separate attention.

Inflammatory Bowel Disease and Eye Involvement

Psoriasis shares inflammatory biology with Crohn’s disease and ulcerative colitis, and patients with psoriasis have a higher-than-average risk of developing inflammatory bowel disease. This overlap has practical treatment implications, since some psoriasis medications also treat IBD, while others can occasionally worsen gut symptoms.

Uveitis, an inflammation inside the eye, is another recognized association, particularly in patients who also have psoriatic arthritis. Sudden eye pain, redness, or vision changes in someone with psoriasis warrant prompt ophthalmology evaluation rather than a wait-and-see approach.

Liver and Kidney Health

Nonalcoholic fatty liver disease appears more frequently in people with moderate to severe psoriasis, likely reflecting shared metabolic and inflammatory drivers rather than a direct cause-and-effect relationship. Chronic kidney disease has also been reported at higher rates in psoriasis populations, particularly in those with longstanding, poorly controlled disease.

These associations add further weight to the argument for routine bloodwork, discussed under investigations, even in patients who feel physically well. Silent organ-level changes are, by definition, not something a patient can detect without testing.

Taken together, these associations explain why dermatologists increasingly view psoriasis management as whole-body care. Treating the skin alone, without addressing these broader risks, is now considered incomplete care.

Investigations: How Psoriasis Is Diagnosed

Psoriasis is primarily a clinical diagnosis, made by an experienced clinician examining the skin, scalp, and nails. However, several supporting investigations play an important role, especially in atypical or severe cases.

Clinical Examination

A thorough skin exam remains the cornerstone of diagnosis. Dermatologists look for characteristic plaque distribution, the Auspitz sign (pinpoint bleeding when scale is removed), and nail changes.

Skin Biopsy

When the diagnosis is unclear, a small skin biopsy can confirm psoriasis and rule out mimicking conditions such as eczema, fungal infection, or cutaneous lymphoma. Histopathology typically shows epidermal thickening, elongated rete ridges, and characteristic inflammatory cell patterns.

Laboratory Testing

Blood tests are not used to diagnose psoriasis itself but are essential before and during systemic treatment. Baseline testing typically includes a complete blood count, liver and kidney function tests, and screening for hepatitis B, hepatitis C, and tuberculosis before starting certain systemic or biologic drugs.

Lipid profiles, fasting glucose, and blood pressure checks are also recommended given the metabolic associations discussed above. Ongoing monitoring, at intervals set by the treating physician, continues throughout systemic therapy.

Imaging for Joint Involvement

When psoriatic arthritis is suspected, X-rays, ultrasound, or MRI may be used to assess joint damage and inflammation. Early imaging can catch joint erosion before it becomes clinically obvious, supporting earlier, more effective treatment.

Severity and Quality-of-Life Scoring

Beyond diagnosis, clinicians use structured tools to track disease over time. PASI and BSA measure physical severity, while the Dermatology Life Quality Index (DLQI) captures the disease’s impact on daily functioning and emotional wellbeing.

The Comorbidity Screening Panel

Given the systemic disease patterns described above, comprehensive psoriasis care extends well beyond skin and joint checks. A thorough workup typically includes blood pressure measurement, body mass index tracking, fasting glucose or HbA1c, and a lipid panel, ideally repeated on a regular schedule.

Mental health screening, using brief validated questionnaires for depression and anxiety, is increasingly built into routine visits as well. None of these tests diagnose psoriasis itself, but together they build a complete picture of a patient’s overall risk profile, which is central to preventing the complications discussed later in this guide.

Treatments for Psoriasis

Psoriasis treatment follows a step-up approach, starting with the least invasive options and escalating based on severity and treatment response. The goal is not just visible skin clearance, but also long-term control of the underlying inflammation.

Topical Treatments

For mild disease, topical therapy is usually the first line of treatment. Mild psoriasis, defined as affecting less than 3% to 5% of body surface area, is generally treated with topical treatments and targeted phototherapy.

Common topical options include corticosteroids, vitamin D analogues (such as calcipotriene), topical retinoids, and calcineurin inhibitors for sensitive areas. Combination products are frequently used to boost effectiveness while limiting side effects.

Certain combinations are specifically supported by clinical evidence. A randomized trial showed that combining tazarotene gel with clobetasol propionate ointment was more effective than tazarotene alone in maintaining clearance after 20 weeks of use.

Some ingredients should not be combined, however. Simultaneous use of salicylic acid with calcipotriene should be avoided, since the acidic pH of salicylic acid inactivates calcipotriene and reduces its effectiveness — a good example of why treatment plans need professional oversight.

Phototherapy

Phototherapy uses controlled ultraviolet light exposure to slow skin cell turnover and reduce inflammation. Narrowband UVB is the most commonly used form and has a strong safety record when properly supervised.

PUVA therapy, which combines a light-sensitizing medication with UVA exposure, is another option, generally reserved for more resistant cases. Because of skin cancer risk with cumulative UV exposure, phototherapy requires ongoing dermatologist supervision and dose tracking.

Systemic Non-Biologic Therapies

For moderate to severe disease not controlled by topicals or phototherapy alone, oral systemic medications may be used. These include methotrexate, cyclosporine, acitretin, and apremilast, each with distinct mechanisms, benefits, and monitoring requirements.

Methotrexate, one of the oldest systemic options, requires regular blood testing to monitor liver function and blood counts. Cyclosporine is fast-acting but generally used short-term due to kidney and blood pressure risks with prolonged use.

Biologic Therapies

Biologics have transformed moderate to severe psoriasis treatment over the past two decades. These injectable or infused medications target specific parts of the immune pathway described earlier in this guide, rather than suppressing the immune system broadly.

Biologic agents, used alone or combined with other topical or systemic medications, have a high benefit-to-risk ratio, making them a valuable addition to the psoriasis treatment toolkit, according to joint AAD-NPF guidelines. Several classes exist, each targeting a different inflammatory messenger.

TNF-alpha inhibitors (such as etanercept, adalimumab, and infliximab) were among the first biologics approved for psoriasis. Etanercept is recommended as a monotherapy option for moderate-to-severe plaque psoriasis, including disease affecting the scalp and nails, and is also recommended for psoriasis of any severity when significant psoriatic arthritis is present.

IL-17 inhibitors (such as secukinumab and ixekizumab) act further downstream in the inflammatory cascade. Because they act more directly on the psoriatic inflammatory cascade, IL-17 inhibitors tend to provide disease-specific treatment with a relatively rapid onset of action.

IL-23 inhibitors (such as guselkumab, risankizumab, and tildrakizumab) target the pathway’s upstream trigger. Because IL-23 inhibition does not affect all mechanisms of IL-17 production, this class does not appear to increase the risk of candidiasis observed in a small percentage of patients on IL-17A inhibitors.

IL-12/23 inhibitors (ustekinumab) block a shared subunit used by both cytokines and remain a well-established option, particularly for patients with certain comorbidities. Choice among biologics depends on disease pattern, joint involvement, comorbidities, and patient preference, always guided by a dermatologist.

Small-Molecule Oral Therapies

Newer oral options, including apremilast and deucravacitinib, offer a middle ground between topical treatment and injectable biologics. These act on specific intracellular signaling pathways and may suit patients who prefer oral dosing or are not candidates for injectable therapy.

Lifestyle and Adjunct Measures

Medical treatment works best alongside supportive lifestyle measures. Maintaining a healthy weight, limiting alcohol, avoiding smoking, managing stress, and using regular moisturizers can meaningfully reduce flare frequency and severity.

None of these lifestyle measures replace medical treatment for moderate to severe disease. They work best as a complement to, not a substitute for, a dermatologist-guided treatment plan.

The “Treat-to-Target” Approach

Modern psoriasis care increasingly follows a treat-to-target model, similar to approaches used in diabetes or hypertension. Rather than accepting “some improvement,” physicians and patients set a specific goal, often 90% or greater skin clearance by a defined time point, and adjust treatment if that goal is not met.

This approach has meaningfully raised expectations for what “good control” should look like. Patients who have lived with partially controlled psoriasis for years are sometimes surprised to learn that near-complete clearance is now a realistic, standard goal for most people with access to appropriate treatment.

Why Treatment Monitoring Schedules Matter

Each drug class carries its own monitoring requirements, and skipping these checks is one of the most preventable causes of treatment complications. Methotrexate typically requires periodic liver enzyme and blood count checks; biologics require periodic infection screening and symptom review; phototherapy requires cumulative dose tracking to limit skin cancer risk.

These schedules are not arbitrary paperwork. They exist because early detection of a laboratory abnormality, well before a patient feels unwell, is what allows a medication to be adjusted safely rather than stopped abruptly after harm has occurred.

Adherence: The Overlooked Variable

Even the most effective medication cannot work if it is not used correctly. Missed doses, inconsistent topical application, and gaps between biologic injections are common, real-world reasons treatments appear to “stop working” when the underlying issue is adherence rather than drug failure.

Open conversations with a treating physician about barriers to adherence — cost, injection anxiety, forgetfulness, complicated regimens — often lead to practical solutions. This is another concrete reason regular follow-up appointments matter more than they might initially seem to.

Limitations of Current Treatments

Despite major advances, psoriasis treatment still has real limitations that patients should understand. Setting realistic expectations helps avoid frustration and treatment discontinuation.

No current treatment offers a permanent cure. Even highly effective biologics generally require ongoing, indefinite use to maintain clear skin, and disease typically returns after stopping treatment.

Response varies significantly between individuals. A biologic that works well for one patient may be only partially effective for another, sometimes requiring a switch to a different drug class entirely.

Cost and access remain significant barriers. Biologic therapies are expensive, and insurance coverage, prior authorization requirements, and geographic access to specialists can all delay effective treatment.

Long-term safety data, while reassuring for most biologics, are still accumulating for newer agents. This is another reason ongoing monitoring, discussed in more detail below, is not optional but essential.

Finally, treatments that work well for skin disease do not always control joint or systemic disease equally well, and vice versa. This is why treatment selection should account for the full pattern of a patient’s disease, not skin severity alone.

Secondary Loss of Response

A treatment that works well initially can sometimes lose effectiveness over time, a phenomenon dermatologists call secondary loss of response. This is thought to relate, in part, to the immune system producing antibodies against certain biologic drugs, particularly when doses are missed or spaced irregularly.

When this happens, physicians typically consider dose adjustment, adding a second medication, or switching to a different drug class entirely. Recognizing secondary loss of response early, rather than assuming the disease has simply “gotten worse,” is another reason consistent follow-up matters.

Comorbidities Can Limit Options

Some highly effective psoriasis medications are unsuitable for patients with certain coexisting conditions. For example, methotrexate is generally avoided in significant liver disease, and some biologics require caution in patients with a history of certain infections, demyelinating disease, or heart failure.

This means treatment selection is rarely a simple “most effective drug” decision. It is instead a careful matching process between a specific patient’s full health picture and the risk-benefit profile of each available option, which is precisely the kind of judgment call that benefits from specialist expertise rather than self-directed treatment choices found online.

Complications and the Psoriatic March

Beyond the skin and joints, unmanaged psoriasis appears to set off a cascade of downstream health effects. Researchers describe this chain reaction using a specific term: the psoriatic march.

What Is the Psoriatic March?

The concept was first proposed to explain psoriasis’s link to heart disease. It suggests a causal link between psoriasis as a systemic inflammatory condition and cardiovascular comorbidity, in which systemic inflammation may cause insulin resistance, which in turn triggers endothelial cell dysfunction.

From there, the chain continues toward more serious outcomes. That same endothelial dysfunction can lead to atherosclerosis and, ultimately, myocardial infarction or stroke, according to the original framework proposed by Boehncke and colleagues.

Obesity plays a reinforcing role in this cycle. Psoriasis and its comorbidities, primarily obesity, contribute to the inflammatory burden of the affected patient, and systemic inflammation in turn causes insulin resistance, feeding the cycle further.

Supporting Biological Evidence

This isn’t just a theoretical model; laboratory findings support the connection. Psoriatic patients show increased inflammatory serum markers, and circulating biomarkers such as C-reactive protein, erythrocyte sedimentation rate, and the platelet activation marker P-selectin positively correlate with disease severity.

Vascular tissue studies reinforce the link at a cellular level. The cytokine profiles of psoriasis skin lesions and atherosclerotic vascular lesions are remarkably similar, both showing increased numbers of Th1 and Th17 lymphocytes, suggesting shared inflammatory drivers.

Why Treatment May Interrupt the March

This is not a one-way street toward inevitable complications. Effective, sustained anti-inflammatory treatment may help interrupt the cycle before it progresses.

Continuous, effective systemic therapy may stop the psoriatic march by interfering with insulin resistance and the downstream vascular damage it drives. This finding is one of the strongest arguments for early, adequate, and consistently monitored treatment rather than a reactive, flare-by-flare approach.

Other Notable Complications

Beyond cardiovascular disease, psoriasis complications can include chronic kidney disease, nonalcoholic fatty liver disease, certain lymphomas (rarely), and eye conditions such as uveitis. Skin infections can also occur, particularly in cracked or excoriated plaques.

Because these complications often develop silently, regular screening — not just skin checks — is a core part of responsible psoriasis care.

Skin-Level Complications

Chronic scratching and cracked plaques create openings for bacterial and, less commonly, viral skin infections. Thickened plaques over joints, particularly on the hands and feet, can also crack painfully, sometimes limiting daily activities like walking or gripping objects.

Long-standing, poorly controlled plaques can occasionally lead to permanent pigment changes even after the underlying inflammation clears, particularly in skin of color as discussed above. This is one more argument for early, adequate treatment rather than tolerating visible disease for extended periods.

Mortality Data

Population-level studies have found that patients with severe psoriasis have a modestly higher overall mortality risk compared to the general population, driven largely by the cardiovascular and metabolic complications discussed throughout this guide. This risk appears most pronounced in patients with long-standing, severe, undertreated disease, reinforcing that psoriasis deserves the same long-term seriousness of management as other major chronic inflammatory diseases.

Psychological Aspects of Psoriasis

The emotional toll of psoriasis is sometimes underestimated compared to its physical symptoms. Visible, chronic skin disease affects self-esteem, relationships, and mental health in ways that deserve dedicated clinical attention.

The Scale of the Impact

Studies consistently show elevated rates of depression and anxiety among people with psoriasis compared to the general population. This appears related both to visible disfigurement and to the biological effects of chronic systemic inflammation on brain chemistry.

Sleep disturbance is common too, driven by itching, discomfort, and joint pain. Poor sleep, in turn, can worsen mood and even amplify inflammatory processes, creating another feedback loop.

Social and Occupational Effects

Stigma remains a real barrier for many patients. Some report avoiding swimming, physical intimacy, certain clothing, or social situations due to visible plaques, and workplace discrimination has been documented in surveys of patients with psoriasis.

Quality-of-life tools like the DLQI, mentioned earlier under investigations, exist precisely because these psychosocial effects are measurable and clinically meaningful. A DLQI score comparable to major chronic diseases is common in people with moderate to severe psoriasis.

Why Mental Health Screening Belongs in Psoriasis Care

Given these patterns, many dermatology guidelines now recommend routine screening for depression and anxiety in psoriasis patients. Addressing mental health is not separate from treating psoriasis; it is part of treating it properly.

Patients experiencing persistent low mood, anxiety, or thoughts of self-harm should raise this directly with their treating physician. Effective skin-directed treatment often improves mood, but dedicated mental health support may also be needed alongside it.

Practical Coping Strategies

Beyond formal treatment, several practical strategies can support day-to-day wellbeing. Connecting with others who understand the condition, whether through patient support groups or online communities, is one of the most consistently reported sources of comfort for patients.

Learning simple language to explain psoriasis to curious or concerned acquaintances can also reduce social anxiety over time. Many patients find that a short, matter-of-fact explanation — “It’s a chronic immune condition, not contagious” — helps defuse awkward moments quickly.

Cognitive behavioral therapy has evidence specifically in dermatology settings for reducing the psychological burden of chronic skin disease. Mind-body techniques such as mindfulness-based stress reduction have also shown modest benefit for both mood and, in some studies, flare frequency.

Living With Psoriasis: Daily Management

Alongside formal medical treatment, everyday habits shape how psoriasis feels and behaves day to day. This section brings together practical guidance dermatologists commonly give patients.

Skin Care Basics

Daily moisturizing, ideally with fragrance-free, thick emollients applied right after bathing, helps reduce scaling, cracking, and itch. Lukewarm rather than hot water during bathing helps avoid stripping natural oils that protect the skin barrier.

Gentle pat-drying, rather than vigorous rubbing, reduces the friction that can trigger the Koebner phenomenon described earlier. Fragrance-free, dye-free skin products in general are usually gentler on already-inflamed skin.

Sun Exposure, Sensibly

Moderate, controlled sun exposure can improve psoriasis for many patients, echoing the mechanism behind medical phototherapy. However, sunburn is a well-documented trigger for new plaques, so sun protection on unaffected skin, along with cautious, gradual exposure, is the generally recommended balance.

Clothing and Environmental Choices

Soft, breathable fabrics reduce friction-related irritation, particularly over plaque-prone areas like elbows and knees. Humidifiers can help in dry indoor environments, especially during winter months when many patients notice worsening symptoms.

Diet and Weight Management

While no single “psoriasis diet” is medically proven to control disease, achieving and maintaining a healthy body weight has real, evidence-supported benefits. Weight loss in patients with overweight or obesity has been shown in clinical studies to improve response to several systemic psoriasis treatments, likely by reducing background inflammation.

Alcohol reduction is another well-supported recommendation, since alcohol is associated with both flare frequency and reduced treatment response in some studies. These lifestyle factors work best as part of a broader treatment plan, not as standalone alternatives to medical therapy.

Building a Long-Term Care Routine

Many patients benefit from keeping a simple flare diary, noting triggers, stress levels, and treatment changes alongside symptom severity. Over months, this can reveal personal patterns that are easy to miss day to day, and it gives the treating physician concrete information to refine the treatment plan.

Consistency, patience, and open communication with a care team tend to matter more for long-term outcomes than any single product or remedy. This theme — the value of a sustained, professionally guided relationship — carries directly into the next section.

Why Psoriasis Needs Constant Doctor Monitoring

Psoriasis is a lifelong condition that changes over time, which is why ongoing medical supervision matters far more than a single diagnosis and prescription. Several concrete reasons explain why.

Disease activity fluctuates. Psoriasis can flare or improve based on stress, infection, hormones, weather, or medication changes, meaning treatment plans often need periodic adjustment.

Systemic risks accumulate silently. Cardiovascular, metabolic, and liver risks discussed throughout this guide often develop without obvious symptoms, so regular checkups catch problems before they become serious.

Treatments require safety monitoring. Many systemic and biologic therapies need periodic blood tests, infection screening, and vaccination review to catch side effects early and adjust dosing safely.

Joint disease can develop later. Psoriatic arthritis sometimes appears years after skin symptoms begin, so ongoing follow-up allows early detection and treatment before joint damage becomes permanent.

Life stages change treatment needs. Pregnancy planning, aging, and new health diagnoses can all require a treatment plan to be revisited and adjusted, sometimes urgently.

Mental health needs evolve. As discussed above, psychological impact can shift independently of skin severity, and regular contact with a care team creates opportunities to catch and address this early.

In short, psoriasis is best managed as a long-term partnership between patient and physician, not a one-time prescription. Skipping follow-up care is one of the most common — and most preventable — reasons for poor long-term outcomes.

What a Typical Follow-Up Schedule Looks Like

While exact timing depends on treatment and disease severity, many patients on systemic or biologic therapy are seen every three to six months once stable, with more frequent visits during initial treatment or dose changes. Annual comorbidity screening, covering the metabolic and cardiovascular checks described earlier, is a common baseline even for patients whose skin is well controlled.

Patients on topical treatment alone for mild disease may need less frequent visits, but periodic check-ins remain valuable, since psoriasis patterns and severity can shift over months or years. Bringing a symptom or flare diary, mentioned earlier, to these appointments often makes each visit more productive.

Shared Decision-Making

The best long-term outcomes tend to come from a genuinely collaborative relationship, where patients feel comfortable raising concerns about side effects, cost, or quality of life, and physicians adjust plans accordingly. Psoriasis treatment today offers more options than ever before, which means there is usually a workable path forward even when a first or second treatment does not fit well.

Patients who feel unheard or whose current treatment plan does not match their goals should feel empowered to discuss this directly with their dermatologist, or seek a second opinion. Persistent, unresolved dissatisfaction with a treatment plan is itself a reason for a follow-up conversation, not something to simply endure.

Prognosis and Long-Term Outlook

Psoriasis is, by nature, a lifelong condition with a relapsing-remitting course, meaning periods of flare alternate with periods of improved or clear skin. The long-term outlook, however, has changed dramatically for the better over the past two decades.

Disease Course Over Time

For many patients, disease severity and pattern shift over a lifetime rather than remaining static. A person with mild plaque psoriasis in their twenties may experience a more widespread flare during a stressful life event decades later, or may see gradual improvement with age and sustained treatment.

Guttate psoriasis in children and young adults sometimes resolves completely and never returns, while in others it evolves into chronic plaque disease. This variability is part of why ongoing reassessment, rather than a fixed treatment plan set once and never revisited, fits the real nature of the disease.

The Modern Treatment Era

Patients diagnosed today have access to a far broader and more effective treatment landscape than those diagnosed even fifteen years ago. Biologic therapies targeting the IL-23/Th17 axis described earlier in this guide have shifted realistic treatment goals from “manageable” to “clear or nearly clear skin” for most patients with access to appropriate care.

This shift has also changed how seriously the systemic dimensions of psoriasis are treated. Cardiovascular risk reduction, mental health support, and joint protection are now considered integral parts of psoriasis care, not optional add-ons, reflecting the broader understanding of the disease covered throughout this guide.

Setting Realistic, Personalized Goals

Because psoriasis varies so much between individuals, prognosis conversations work best when personalized rather than generic. Factors such as disease severity at diagnosis, presence of psoriatic arthritis, comorbidities, and treatment access all shape what a realistic long-term goal looks like for any given patient.

A dermatologist who knows a patient’s full history is best positioned to set these expectations accurately and to adjust them as circumstances change. This individualized, ongoing approach is, once again, why sustained medical partnership — rather than a single visit or a generic online treatment plan — remains the foundation of good psoriasis care.

Common Myths About Psoriasis

Misinformation about psoriasis remains widespread, and it can delay proper treatment or fuel unnecessary stigma. Addressing a few persistent myths directly is worthwhile.

Myth: Psoriasis is just dry skin. Psoriasis is an immune-mediated disease driven by internal inflammatory signaling, not simply a lack of moisture, even though dryness can worsen how plaques feel and look.

Myth: Poor hygiene causes psoriasis. Psoriasis has nothing to do with cleanliness; it is driven by genetic and immune factors described earlier in this guide, and no amount of washing prevents or clears it.

Myth: Psoriasis only affects older adults. As covered in the pediatric section, roughly a third of cases begin before age 20, and disease can first appear at almost any point in life.

Myth: Natural remedies alone can cure psoriasis. While supportive lifestyle measures genuinely help manage symptoms, no natural remedy has been shown to cure or fully replace medical treatment for moderate to severe disease.

Myth: All psoriasis treatments are equally strong. Treatment options span an enormous range, from mild topical creams to advanced biologic therapy, and matching the right option to the right severity is central to good outcomes.

Myth: Once psoriasis clears, it is gone for good. Psoriasis is a chronic condition, and ongoing treatment is usually needed to maintain clearance even after skin looks completely normal.

Correcting these misconceptions matters beyond individual understanding. Persistent myths can lead patients to delay seeing a dermatologist, try ineffective remedies, or discontinue effective treatment prematurely, all of which work against the long-term, well-monitored approach this guide has emphasized throughout.

Myth: Stress is “all in your head” and irrelevant to treatment. Stress has a measurable, biological effect on the immune pathways driving psoriasis, so stress management is a legitimate, evidence-informed part of a treatment plan rather than an afterthought.

Recognizing myths for what they are — and replacing them with accurate, source-backed information — is part of what makes a resource like this one genuinely useful, rather than just another list of surface-level tips.

Frequently Asked Questions

---

Sources and References

1. World Psoriasis Day Consortium / Global Psoriasis Prevalence Data — Research and Markets, Psoriasis Epidemiology Forecast 2025–2034.
2. Global Psoriasis Atlas (GPA), Third Edition, World Psoriasis Day 2025 — globalpsoriasisatlas.org.
3. HCPLive, “Psoriasis Incidence Projected to Increase by 2025 Across Various Groups,” December 2025.
4. Medscape, “Global Psoriasis Incidence Projected to Rise Through 2050,” November 27, 2025.
5. Xiong et al., “Dynamic trend analysis of global psoriasis burden from 1990 to 2021,” Frontiers in Public Health, July 2025.
6. Rare Disease Advisor, “Burden of Psoriasis Continues to Increase Despite Treatment Advances,” July 2025.
7. “Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study,” PMC.
8. “Global Burden of Psoriasis from 1990 to 2021 and Potential Factors: A Systematic Analysis,” PubMed.
9. Girolomoni G. et al., “The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis,” Journal of the European Academy of Dermatology and Venereology, 2017.
10. “The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses,” PMC.
11. “Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities,” Dermatology and Therapy / Springer, 2021.
12. “Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis,” PMC.
13. “Review: A Contemporary, Multifaceted Insight into Psoriasis Pathogenesis,” PMC.
14. “The Immunology of Psoriasis—Current Concepts in Pathogenesis,” Clinical Reviews in Allergy & Immunology, 2024.
15. Boehncke W-H. et al., “The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity,” Experimental Dermatology, 2011.
16. “Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?” Frontiers in Immunology, 2022.
17. “Psoriatic march: A view from pathophysiology to cardiovascular risk,” Revista Colombiana de Reumatología, 2024.
18. “Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment,” International Journal of Molecular Sciences (MDPI), 2017.
19. Menter A. et al., “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics,” Journal of the American Academy of Dermatology, 2019.
20. Elmets C.A. et al., “Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures,” Journal of the American Academy of Dermatology, 2021.
21. National Psoriasis Foundation, “Psoriasis Guidelines” and clinical guidance summaries — psoriasis.org.
22. ClinicalTrials.gov protocol, “A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis” (background section on treatment guidelines).
23. DermNet, “Treatment of Psoriasis in Pregnancy: A Complete Overview.”
24. “Impetigo herpetiformis,” ScienceDirect Topics.
25. “A case of impetigo herpetiformis in which termination of pregnancy was required,” PMC.
26. HealthCentral, “Psoriasis During Pregnancy: Risks, Management, and Treatment,” January 2025.
27. Namazi N., Dadkhahfar S., “Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment,” 2018.
28. DermNet, “Biologics and Novel Small Molecule Treatments: Reproduction and Psoriasis.”
29. “Impetigo Herpetiformis Complicating Pregnancy: A Case Report on a Rare Gestational Dermatosis With Constitutional Symptoms,” PMC.
30. “An arcane presentation of pustular psoriasis in pregnancy: case report,” PMC.
31. Boehncke W-H., Gladman D.D., Chandran V., “Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda,” The Journal of Rheumatology, 2011.
32. National Psoriasis Foundation, “About Psoriasis” and “Psoriasis Statistics” — psoriasis.org.
33. DermNet, “Psoriasis” overview and clinical subtype reference pages — dermnetnz.org.

This article is intended for general educational purposes and does not replace personalized medical advice. Anyone with psoriasis or symptoms suggestive of psoriasis should consult a board-certified dermatologist for diagnosis and an individualized treatment plan. Recommendations for specific medications, dosing, and monitoring schedules should always be confirmed with a treating physician familiar with the patient’s complete medical history, since individual circumstances can meaningfully change what is safe and appropriate.